Canopy Biosciences develops and commercializes research tools focused on gene editing and expression analysis. The company was founded in September 2016 and operates out of the BioGenerator Labs in St. Louis, Missouri. Its lead technology is licensed through Washington University in St. Louis and it already serves customers in Europe, India, Japan, and South Korea. Canopy has demonstrated a rapid path to revenue, launching four product lines and two services within the past year. The company plans to use new funding to develop additional research tools, commercialize cutting-edge products, and hire more employees. Canopy was founded by Edward Weinstein, David Smoller, and Crystal Winkeler.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

May 2018